My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2024_OpioidSettlemtAgrmt_JanssenJJ
>
Meetings
>
2024
>
04. April
>
2024-04-16 10:00 AM - Commissioners' Agenda
>
2024_OpioidSettlemtAgrmt_JanssenJJ
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
4/11/2024 1:10:33 PM
Creation date
4/11/2024 1:08:48 PM
Metadata
Fields
Template:
Meeting
Date
4/16/2024
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Accepting the Johnson & Johnson (Janssen) Washington State State-Wide Opioid Settlement Agreement
Order
7
Placement
Consent Agenda
Row ID
116716
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
127
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
<br />J-9 <br /> <br /> <br />5. Provide evidence-informed treatment, including MAT, recovery support, harm <br />reduction, or other appropriate services to individuals with OUD and any co- <br />occurring SUD/MH conditions who are leaving jail or prison or have recently left jail <br />or prison, are on probation or parole, are under community corrections supervision, or <br />are in re-entry programs or facilities. <br />6. Support critical time interventions (“CTI”), particularly for individuals living with <br />dual-diagnosis OUD/serious mental illness, and services for individuals who face <br />immediate risks and service needs and risks upon release from correctional settings. <br />7. Provide training on best practices for addressing the needs of criminal justice- <br />involved persons with OUD and any co-occurring SUD/MH conditions to law <br />enforcement, correctional, or judicial personnel or to providers of treatment, recovery, <br />harm reduction, case management, or other services offered in connection with any of <br />the strategies described in this section. <br />E. ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND <br />THEIR FAMILIES, INCLUDING BABIES WITH NEONATAL ABSTINENCE <br />SYNDROME <br />Address the needs of pregnant or parenting women with OUD and any co-occurring <br />SUD/MH conditions, and the needs of their families, including babies with neonatal <br />abstinence syndrome (“NAS”), through evidence-based or evidence-informed programs <br />or strategies that may include, but are not limited to, those that: <br />1. Support evidence-based or evidence-informed treatment, including MAT, recovery <br />services and supports, and prevention services for pregnant women—or women who <br />could become pregnant—who have OUD and any co-occurring SUD/MH conditions, <br />and other measures to educate and provide support to families affected by Neonatal <br />Abstinence Syndrome. <br />2. Expand comprehensive evidence-based treatment and recovery services, including <br />MAT, for uninsured women with OUD and any co-occurring SUD/MH conditions for <br />up to 12 months postpartum. <br />3. Provide training for obstetricians or other healthcare personnel who work with <br />pregnant women and their families regarding treatment of OUD and any co-occurring <br />SUD/MH conditions. <br />4. Expand comprehensive evidence-based treatment and recovery support for NAS <br />babies; expand services for better continuum of care with infant-need dyad; and <br />expand long-term treatment and services for medical monitoring of NAS babies and <br />their families. <br />5. Provide training to health care providers who work with pregnant or parenting women <br />on best practices for compliance with federal requirements that children born with <br />NAS get referred to appropriate services and receive a plan of safe care.
The URL can be used to link to this page
Your browser does not support the video tag.